Drug Information

Drug General Information
Drug ID
D0Q3VE
Former ID
DIB015542
Drug Name
PF-04971729
Synonyms
PF-4971729; SGLT2 inhibitor (oral, type 2 diabetes), Pfizer; Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 3 [524892]
Company
Merck; pfizer
Formula
C22H25ClO7
InChI
InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
InChIKey
MCIACXAZCBVDEE-CUUWFGFTSA-N
PubChem Compound ID
44814423
PubChem Substance ID
89442948, 120130619, 131281547, 131345821, 140604034, 162011560, 162108670, 162205143, 163312343, 174526435, 185978788, 198984080, 210024075, 223404370, 223471394, 224604107, 226541727, 243511761, 252109952, 252166588, 252448906
Target and Pathway
Target(s) SLGT2 Target Info Modulator
Reactome Hexose transport
Na+-dependent glucose transporters
Inositol transporters
WikiPathways NRF2 pathway
Nuclear Receptors Meta-Pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
References
Ref 524892ClinicalTrials.gov (NCT02226003) Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017). U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.